|
|
|
|
|
|
|
|
Dabstract/open access
Objective: The objective of this study was to compare
immunohistochemical profile for the apoptosis regulators p53, C-MYC,
bax, PUMA, and PTEN and the cell cycle regulatory proteins p21 and p27,
as well as clinical factors between types I and II tumors.
Methods:
In total, 131 patients in FIGO (International Federation of Gynecology
and Obstetrics) stages I-II were divided into 2 groups of patients after
type I tumors (n = 79) and type II tumors (n = 52). Differences in the
immunohistochemical profile for the cell cycle–related proteins,
detected by tissue microarrays and immune-histochemistry, were compared.
For statistical tests, the Pearson χ2 test and the logistic regression model were used. All tests were 2-sided, and the level of statistical significance was P ≤ 0.05.
Results:
In multivariate logistic regression analysis with recurrent disease as
endpoint, FIGO stage (odds ratio [OR], 4.7), type I/II tumors (OR, 3.8),
body mass index (BMI) (OR, 3.5), and p53 status (OR, 4.2) all were
found to be independent predictive factors. In 2 different multivariate
logistic regression analyses with type I/II tumors as endpoint, both p53+p21−
(OR, 2.9) and p27 status (OR, 3.0) were associated with type II tumors.
Differently, C-MYC status (OR, 0.4) was associated with type I tumors.
Furthermore, age (OR, 1.04), BMI (OR, 0.4), and recurrent disease (OR,
4.3) all were associated to type II tumors. In survival analysis, there
was a trend (P = 0.054) toward better disease-free survival for patients with type I tumors.
Conclusions: Concomitant positivity for p53 and
negativity for p21, positivity for p27, and negativity for C-MYC in an
epithelial ovarian tumor might strengthen the diagnostic option of type
II tumor ovarian carcinoma. Patients with type II tumors were older, had
lower BMI, and had more often recurrent disease than patients with type
I tumors.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.